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Background:  Cocaine  has become  one  of  the drugs  of  most  concern  in  Switzerland,  being associated
with  a wide  range  of  medical,  psychiatric  and  social  problems.  Available  treatment  options  for  cocaine
dependence  are  rare.  The  study  sought  to compare  combined  prize-based  contingency  management
(prizeCM)  plus  cognitive-behavioral  therapy  (CBT)  to CBT alone  in  cocaine-dependent  patients.
Methods:  Sixty  cocaine-dependent  patients  participated  in  a randomized,  controlled  trial with  two  treat-
ment conditions.  The  participants  were  randomly  assigned  to  the  experimental  group  (EG;  n  =  29), who
received  CBT  combined  with  prizeCM,  or to the control  group  (CG;  n  = 31),  who  received CBT only  during
24  weeks.  The  primary  outcome  measures  were  retention,  at least  3  consecutive  weeks  of cocaine  absti-
nence,  the  maximum  number  of  consecutive  weeks  of  abstinence  and  proportions  of cocaine-free  urine
samples  during  the entire  24-week  and  at 6-month  follow-up.
Results:  Sixty-three  percent  of  the  participants  completed  the  study  protocol.  Participants  in both  groups
signiﬁcantly  reduced  cocaine  use  over  time.  Overall,  no difference  in cocaine-free  urine  screens  was  found
across  the two  treatment  groups,  except  at weeks  8, 9, 10,  17  and 21 in  favor  of  the  EG.
Conclusions:  The  addition  of  prizeCM  to  CBT  seems  to enhance  treatment  effects,  especially  in  the early
treatment  period,  supporting  results  from  previous  studies.  Both  the  combined  intervention  and  CBT
alone,  led  to  signiﬁcant  reductions  in  cocaine  use  during  treatment  and these  effects  were sustained  at
6-month  follow-up.  These  ﬁndings  underline  the  importance  in implementing  CM  and  CBT  interventions
as  treatment  options  for cocaine  dependence  in the European  context.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
Cocaine is, after cannabis, the second most commonly used illicit
rug in Europe. Approximately 4.1% of citizens aged between 15
nd 64 years have used cocaine at least once in their lives. Swiss
ities like Zurich, Geneva and Bern have been found to be among
he places where cocaine consumption is highest in Europe, com-
arable to Antwerp and Amsterdam (Osterath, 2012).Cocaine use is associated with numerous medical and psy-
hosocial consequences, including increases in risks of myocardial
nfarction, infectious diseases, comorbid psychiatric disorders,
∗ Corresponding author. Tel.: +41 61 325 54 51; fax: +41 61 325 55 83.
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376-8716/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open
icenses/by-nc-nd/3.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
delinquency and violence (Compton et al., 2007; Macdonald et al.,
2008; Qureshi et al., 2001; Tyndall et al., 2003).
Currently, no pharmacological therapy has been found to be
broadly effective in the treatment of cocaine dependence (for a
review, see Sofuoglu and Kosten, 2006). Conversely, a large body
of evidence supports the efﬁcacy of psychosocial interventions in
treating cocaine dependence. Two of the most promising interven-
tions are contingency management (CM) and cognitive-behavioral
therapy (CBT).
Contingency management interventions are based on behav-
ioral research indicating that when a behavior is reinforced, it
increases in frequency. CM can help to reduce or discontinue
cocaine use (Higgins, 1999). CM (for a review, see Lussier et al.,
2006) and CBT (for a review, see Farronato et al., 2013; Magill
and Ray, 2009) have been proven to be efﬁcacious for treating
 access article under the CC BY-NC-ND license (http://creativecommons.org/
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 variety of substance use disorders. CBT is a psychotherapeutic
pproach to support cocaine-dependent individuals in becoming
bstinent or reducing their cocaine use by enabling them to rec-
gnize risky situations, to avoid these situations, and to cope
ith problems associated with their cocaine use (Carroll, 1998;
ürsteler-MacFarland et al., 2010). While the onset of CM effects is
apid (Robles et al., 2000), the effect of CBT may  not always be visi-
le during active treatment (Rawson et al., 2006). However, within
ne year of ceasing CBT, delayed effects may  become manifest, thus
ndicating improvements in drug-related outcomes (Carroll et al.,
994). Conversely, the effects of CM tend to diminish after discon-
inuation (Rawson et al., 2002). Combining these two treatments
ight produce complementary effects (Epstein et al., 2003; Rawson
t al., 2006). Since almost every trial comparing CBT plus CM to CBT
as performed in the USA, we planned to investigate the accept-
bility and efﬁcacy of CBT plus prizeCM in the European context. It
as hypothesized that participants in the CBT plus prizeCM inter-
ention (experimental group; EG) would show better retention in
reatment, be more likely to attain 3 or more weeks of continuous
ocaine abstinence and have a higher proportion of negative uri-
alyses compared to CBT alone (control group; CG) during active
reatment and at 6-month follow-up.
. Methods
.1. Participants
Of 118 patients screened, 60 cocaine-dependent patients
50.8%) who intended to stop or reduce their cocaine use partic-
pated in the study. These 60 subjects represent enrollment at a
ingle site; there was a second site, but data could not be used due
o integrity concerns. As shown in Fig. 1, almost half (49.2%) of all
creened patients could not be enrolled, either due to failure to
eet study criteria (22.9%) or due to low interest in participation
26.3%). Inclusion criteria for eligibility were cocaine dependence
ccording to the Diagnostic and Statistical Manual of Mental Dis-
rders (DSM-IV; American Psychiatric Association, 1994), at least
ne cocaine-positive urinalysis at baseline, and a minimum age of
8 years. Exclusion criteria were current psychotic disorders, cur-
ent severe alcohol or benzodiazepine dependence, serious medical
llnesses, gambling disorder, medication with methylphenidate,
roblems in language comprehension and homelessness. Addi-
ional concomitant substance use disorders (SUD; e.g. opioids,
lcohol, benzodiazepines, etc.) were no reason for exclusion. The
tudy aimed to investigate a clinical sample to increase generaliza-
ion of the ﬁndings.
The study took place at the Psychiatric Hospital of the Uni-
ersity of Basel from February 2009 until July 2013. Participants
ere recruited at the outpatient unit in Basel City and the region
f Basel, as well as through announcements in local newspapers,
he internet, and radio broadcasts. The study was  approved by
he local ethics committee and conducted in accordance with the
eclaration of Helsinki. All participants provided written informed
onsent before undergoing study procedure. The trial is registered
n www.clinicaltrial.gov (identiﬁcation number NCT00877435).
.2. Study design and general procedures
The study was a prospective, 24-week, randomized, con-
rolled clinical trial comparing CBT plus prizeCM vs. CBT alone in
ocaine-dependent patients. Following informed consent, patients
ompleted a two-week baseline assessment. Patients were then
andomly assigned to one of the two treatment arms using com-
uterized random numbers. The allocation sequence was  provided
n sealed envelopes and thus blind to the researchers and patients.Dependence 145 (2014) 94–100 95
After group allocation, patients received a 12-week intervention
phase (CBT + prizeCM or CBT alone, week 1–12) followed by a
12-week maintenance phase (CBT + prizeCM or CBT alone, week
13–24). Six months after the last visit, patients were re-invited
for a follow-up assessment and received a remuneration of 20$
for their participation (week 48). Patients were excluded by the
study investigator and counted as drop-outs if they were absent
for 3 consecutive weeks without any excuse. Dropout patients had
the possibility of receiving a standard treatment in other treatment
centers in the region of Basel.
2.3. CBT intervention
Patients received 18 manual-guided individual CBT sessions
for 24 weeks, in accordance with the CBT manual by Dürsteler-
MacFarland et al. (2010), as based on the CBT manual by Carroll
(1998). In the ﬁrst 12 weeks, the 60-min therapy sessions took place
weekly and urine samples were collected twice weekly. In weeks
13 to 24, the therapy sessions took place every second week and
urine samples were collected weekly. Urine samples were collected
and analyzed before CBT sessions and performed by the same ther-
apist. Patients received an immediate feed-back about the results
of their urinalyses. Urinalyses were tested onsite for the cocaine
metabolite benzoylecgonine with the drug screen from Stephany
Diagnostika GmbH (Germany). Therapy sessions were conducted
by qualiﬁed psychologists and psychiatrists trained in the CBT
manual for cocaine dependence, all of whom were experienced in
treating substance use disorders. All sessions were rated by thera-
pists and audiotaped and supervised weekly to monitor adherence
to protocol. To monitor clinicians’ skill level, CBT sessions were
videotaped monthly and rated by masters’-level independent eval-
uators.
2.4. Prize-based CM
Prize-based CM was  performed according to the protocol by
Petry (2000) for the entire 24 weeks. According to the frequency
of submitted urine samples patients in the EG had the chance to
earn prizes twice weekly in the intervention phase (1–12 week) and
weekly during the maintenance phase (13–24 weeks). For submit-
ting a cocaine-negative urine sample participants had the chance
to earn prizes of different magnitudes. Patients could draw from
a bowl with 500 chips, of which 250 were non-winning. 219 had
a value of 2$ (mini prizes: food supplies or hygiene articles), 30 a
value of 20$ (medium prizes: vouchers), and the jumbo prize had a
value of $500 (television or holiday vouchers). With the ﬁrst cocaine
free sample, participants earned one draw from the bowl and, with
each subsequent cocaine-negative urine sample, the number of
draws increased until the maximum of 15 draws. A cocaine-positive
urine sample or failure to provide a urine sample led to a reset of
the number of draws to zero.
2.5. Assessment measures
To assess psychiatric comorbidity at baseline, the Structured
Clinical Interview for DSM-IV (Wittchen et al., 1997) was con-
ducted. Furthermore, the Addiction Severity Index (Gsellhofer et al.,
1999) was  carried out at baseline, week 12, week 24, and at 6-month
follow-up. Additionally the Severity of Dependence Scale (SDS), a
5-item scale to measure the degree of dependence (Gossop et al.,
1995) and the Beck Depression Inventory (BDI; Beck et al., 1961)
were assessed at baseline, monthly, and at follow-up. Patients
reported cocaine use (frequency and amount) and cocaine crav-
ing at baseline and weekly. Patients’ satisfaction with CBT sessions
was measured with a 5-point Likert scale (“5” indicates very much
and “1” not at all)  by asking “Are you satisﬁed with the therapy?”
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pFig. 1. Flowchart of participants’ progress through the study allocate
nd “Did the therapy help you?”. Participants in the EG were asked
y using the same 5-point-Likert-scale “Did you like the idea of
rizes?” and “Was the fact that you could win something an addi-
ional incentive for you?”
Changes in personal well-being through therapy were measured
ith a 7-point Likert scale (“7” indicates very much better and “1”
ery worse)  with the question “How do you feel now compared to
tudy start”. Medical assessments were conducted by physicians
nd included blood pressure, heart rate, blood tests and ECG at
aseline.
Primary outcome variables were retention, at least 3 con-
ecutive weeks of cocaine abstinence, the maximum number of
onsecutive weeks of abstinence and proportions of cocaine-free
rine samples during the entire 24-week and at 6-month follow-
p. Secondary outcomes were self-report in cocaine use, craving
cores, changes in the ASI, BDI, SDS scores and patients’ satisfaction
ith the interventions.
.6. Statistical analyses
A power analysis yielded a necessary sample size of 180 patients,
.e. 90 in each group, to detect a statistical difference between the
wo interventions. For this calculation, the standardized difference
f d = 0.42 was taken from a meta-analysis of poly-drug users with
M (Prendergast et al., 2006), the power of 0.80 and a signiﬁcance
evel of  ˛ = 0.05. Statistical analyses were performed using SPSS
oftware (version 19.0 for Windows). Data were basically analyzed
n an intent-to-treat basis if not otherwise speciﬁed. Missed uri-
alyses were coded as positive. All analyses were two-tailed and
he signiﬁcance level was set at  ˛ = 0.05. Non-normally distributed
ata were log or square root transformed. If transformation did not
esult in an improvement, analyses were calculated with original
ata. If assumptions of sphericity or equality of variances were vio-
ated, results were corrected by appropriate correction tests (i.e.
reenhouse–Geisser or tests for unequal variances, where appro-
riate).e experimental group (CBT + prizeCM) or to the control group (CBT).
Group comparison for baseline characteristics were made using
t tests for continuous data, Mann–Whitney U tests for ordinal and
2 tests for nominal data. The total number of cocaine-negative
urine samples submitted was  compared using unpaired t tests.
Cocaine abstinence between the groups was analyzed in different
ways. First, a general estimating equation (GEE) analysis was per-
formed to examine individual changes in weekly cocaine-free urine
samples, varied as a function of treatment group. Second, consecu-
tive weeks of cocaine abstinence were operationalized in categories
(3≥weeks, ≥6 weeks, ≥9 weeks, etc.) and compared by using 2-
tests and the maximum number of consecutive cocaine-free weeks
was compared using the unpaired t test. Weekly proportion of
cocaine-negative urine samples were compared using 2 tests.
Additionally a McNemar test was  used to compare negative uri-
nalyses over time from study start (week 1) to study end (week
24). Treatment retention was  compared between the groups using
a Kaplan–Meier survival analysis (log rank test). A Cox regression
model was calculated to identify predictors for dropout.
For group comparison of clinical measures (e.g. self-report of
cocaine use, craving score, ASI, BDI, and SDS scores), ANOVAs with
two time points were calculated (baseline, week 24), for changes
over time repeated-measurement ANOVAs with four time points
(baseline, week 12, week 24, 6-month follow-up) were calculated
(completer analysis). Patients’ satisfaction with therapy was ana-
lyzed using unpaired t tests.
3. Results
3.1. Baseline characteristics
Study enrollment was  terminated early due to logistical chal-
lenges in recruitment, along with alternate treatment and social
services that were available for patients, and that made the project
problematic to conduct within the available funding time period.
The recruited 60 patients were mostly male (80.1%), of Swiss
nationality (71.7%), had a mean age of 34.5 years, and 56% were
employed (Table 1). The history of cocaine use was  on average 9
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Table  1
Baseline socio-demographic characteristics.
Variablesa CBT + prizeCM
experimental group
(n = 29)
CBT only
control group
(n = 31)
Demographics
Sex (% male) 82.8 77.4
Age  35.3 (7.9) 33.7 (7.5)
Nationality (% Swiss) 82.8 61.3
Marital status (%)
Unmarried 79.3 74.2
Married 13.8 9.7
Divorced/separated 6.9 16.1
Education (%)
No school degree 3.4 0.0
Standard school (9 years) 24.1 32.3
Job  training after school 51.7 41.9
College (≥12 years) 17.2 9.7
University 3.4 16.1
Employment (%)
Employed 62.1 50.0
Disability pension 10.3 13.3
Social security beneﬁts 17.2 13.3
Other 10.3 23.3
a If not otherwise declared, values are mean (SD).
* Signiﬁcant 0.05.
Fig. 2. Proportion of participants with cocaine dependence (n = 60) remaining in
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Table 2
Baseline clinical characteristics.
Variablesa CBT + prizeCM
experimental group
(n = 29)
CBT only
control group
(n = 31)
Cocaine use
Age at ﬁrst cocaine
consumption
25.3 (7.1) 23.0 (5.2)
Years of cocaine
consumption
8.7 (6.0) 9.1 (6.4)
Cocaine use past 7 days (in
days)
2.1 (2.2) 1.6 (1.9)
Cocaine use past 7 days (in
gram)
1.8 (2.3) 1.6 (2.4)
Cocaine craving (0–100) 39.4 (31.6) 32.7 (30.8)
First urine analyses (%
cocaine positive)
72.4 61.3
Route of administration (%)
Intranasal 62.1 54.8
Injection 20.7 29.0
Smoking 17.2 16.1
Psychiatric comorbidity (%)
Axis I diagnosis (non-SUD)b 37.9 54.8
Axis I diagnosis (SUD)c 82.8 77.4
Axis I opioid dependence
(OMT)d
31.0 41.9
Axis II personality disorder 17.2 29.0
Beck Depression Index score 15.3 (8.5) 13.7 (8.9)
Severity of Dependence Scale
score
8.6 (2.7) 8.4 (3.4)
Motivation to quit (0–100) 87.7 (13.1) 85.7 (16.6)
Conﬁdence of achieving
abstinence (0–100)
73.5 (21.6) 68.3 (27.4)
Addiction Severity Index Composite Scores
Medical 0.24 (0.26) 0.27 (0.30)
Employment 0.52 (0.45) 0.69 (0.38)
Alcohol 0.23 (0.19)* 0.13 (0.22)*
Drug 0.20 (0.10) 0.20 (0.10)
Legal 0.07 (0.16) 0.08 (0.16)
Family 0.12 (0.17) 0.17 (0.18)
Psychiatric 0.20 (0.19) 0.21 (0.19)
a If not otherwise declared, values are mean (SD).
b Non-SUD = non-substance use disorder. These are the percents of patients with
cocaine dependence and at least one additional Axis I diagnosis non-substance use
disorder.
c SUD = substance use disorder. These are the percents of patients with cocaine
dependence and at least one additional substance use disorder.
d OMT  = opioid maintenance treatment. These are the percents with an opioidach of two treatment groups over a 24-week randomized clinical trial comparing
BT + prizeCM (experimental group) with CBT (control group).
ears and the psychiatric comorbidity was high, with 80.1% exhibit-
ng an additional SUD, 46.4% axis I disorders (non-SUD) and 23.1%
xis II disorders (Table 2). The baseline demographic and clinical
haracteristics did not differ between the groups, nor did the alco-
ol diagnoses (2(1) = 2.902; p = 0.088). However, participants in the
G exhibited a signiﬁcantly higher ASI alcohol composite score than
he CG (U = 251.5, p = 0.005). The baseline difference in the ASI alco-
ol score was controlled in the GEE models, and there was no effect
n individual treatment outcomes.
.2. Treatment retention
Thirty-eight (63.3%) of 60 participants completed the 24-week
rial (Fig. 2). The overall decline in study retention over time did
ot vary by group. Patients in the EG stayed in treatment for 18.90
SD = 7.92) weeks and those in the CG for 17.45 (SD = 8.71) weeks.
n the EG, 10 out of 29 patients (34.5%) dropped out and in the
G 12 out of 31 (38.7%). Of the 22 drop-outs, 19 (86.4%) droppeddependence diagnosis, and all who did so were on OMT.
* Signiﬁcant 0.05.
out during the intervention and 3 (13.6%) during the maintenance
phase (Fig. 1). Cox regression was conducted to explore predictors
of drop-out from the 24-week trial. Two  baseline variables pre-
dicted dropout signiﬁcantly, namely frequency of cocaine use and
having debts. Patients with more cocaine-using days were 1.2-fold
more likely to drop out (CI 95%: 1.00–1.48) and patients having
debts were 4.5-fold more likely to drop out (CI 95%: 1.04–19.29).
Data from the second site could not be used due to integrity con-
cerns (protocol adherence, incomplete data) though the sample size
was small (n = 20) for this site.
3.3. Cocaine abstinence during the intervention and maintenance
phase
There was no difference of submitted urine samples (maximum
36) between the groups during the 24-week trial, with an average
of 27.28 (SD = 11.32) in the EG compared to 24.74 (SD = 11.65) in
the CG. The EG had a total of 20.21 (SD = 13.10) cocaine-negative
urinalyses (whether consecutive or not). This was greater than the
number for the CG with 16.16 (SD = 12.31), although this difference
was not statistically signiﬁcant.
98 S.A. Petitjean et al. / Drug and Alcohol 
Fig. 3. Distribution of documented, continuous cocaine abstinence observed in each
treatment group during the 24-week randomized clinical trial for participants with
cocaine dependence (n = 60) comparing CBT + prizeCM (experimental group) with
CBT  (control group). The height of each bar represents the percentage of participants
achieving a duration of abstinence greater than or equal to the number of weeks
indicated.
Fig. 4. Proportion of cocaine negative urine samples at baseline, during the 24-week
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The question “Did the therapy help you?” was rated with a meanandomized clinical trial and at 6-month follow-up for participants with cocaine
ependence (n = 60) comparing CBT + prizeCM (experimental group) with CBT (con-
rol group).
Multi-level analyses (GEE model) found no difference between
he groups (Wald-2(1) = 0.31; p = 0.577), and the primary hypoth-
sis had to be rejected. However, negative urinalyses increased
igniﬁcantly over time in both groups (Wald-2(1) = 4.041;
 = 0.044). Patients in the EG attained on average a maximum num-
er of weeks of continuous cocaine abstinence of 8.21 (SD = 8.13)
ompared to 7.06 (SD = 8.01) in the CG. The percentage of patients
chieving three weeks of continuous cocaine abstinence did not dif-
er between treatment groups (Fig. 3; EG, 51.7% vs. CG 54.8%). There
as a trend indicating a higher proportion of 9 or more weeks of
bstinence in the EG group, but this did not reach statistical sig-
iﬁcance (2(1) = 3.337; p = 0.068). In the intervention phase (week
–12), the percentage of patients achieving three weeks of contin-
ous cocaine abstinence was attained by 58.6% of the EG and 45.2%
f patients in the CG and in the maintenance phase (week 13–24)
y 58.6% of the EG and 51.6% of patients in the CG.
However, during the entire 24-week trial signiﬁcant differences
ere found at speciﬁc time points in proportion of cocaine-negative
rine samples (Fig. 4). In week 8 the EG exhibited a signiﬁcantly
igher proportion of cocaine-negative urine samples than the CG
65.5% vs. 38.7%, 2(1) = 4.31; p = 0.038), also in week 9 (62.1%Dependence 145 (2014) 94–100
vs. 32.3%, 2(1) = 5.35; p = 0.021), in week 10 (58.6% vs. 32.3%,
2(1) = 4.21; p = 0.040), in week 17 (58.6% vs. 32.3%, 2(1) = 4.21;
p = 0.040) and in week 21 (55.2% vs. 29.0%, 2(1) = 4.21 p = 0.040).
At the end of the 24-week trial the proportion of cocaine-negative
urine samples in the EG was greater with 55.2% compared to 41.9%
in the CG but did not reach statistical signiﬁcance. With regard to
the self-report measures of cocaine use, no difference between the
groups was detected for frequency (last 7 days), amount of cocaine
(gram) or cocaine craving during the 24-week trial.
Comparison of all negative urinalyses of the total sample (both
groups) from baseline (n = 15; 25%) to week 24 (n = 29; 48.3%) found
a highly signiﬁcant difference (2(1) = 7.26; p = 0.009), indicating a
reduction in cocaine use over time. Effect sizes were calculated
to establish possible effects of the prizeCM. The total number of
cocaine-free days during study time was  compared between the
two groups, resulting in an effect size of d = 0.14, displaying a weak
effect for prizeCM.
3.4. Cocaine abstinence at 6-month follow-up
Forty-nine of 60 participants (81.7%; EG: n = 25; CG:  n = 24)
attended the 6-month follow-up visit (Fig. 1). The percentage of
cocaine-negative urine samples at 6-month follow-up was  higher
in the EG, although statistically not signiﬁcant (EG: 65.5% vs. CG:
45.2%; Fig. 4). Self-report continuous cocaine abstinence did not dif-
fer between the two groups even though patients in the EG achieved
on average of 11.54 (SD = 9.06) weeks compared to 7.83 (SD = 8.97)
weeks in the CG. No difference between the groups was found
in self-report measures of cocaine use, frequency (past 7 days),
amount (in gram) and cocaine craving scores. Repeated-measures
ANOVAs at follow-up showed a signiﬁcant decrease in frequency
of cocaine use over time (F(1.93/55.87) = 5.95, p = 0.005), but no group
difference. Furthermore, a reduction in the amount of cocaine use
(F(2.04/59.08) = 2.861: p = 0.064) was found. Although this failed to
reach statistical signiﬁcance, it might be seen as a trend in favor
of the EG.
3.5. Clinical measures
In the ITT sample, all clinical measures (BDI, SDS, ASI composite
scores) did not differ signiﬁcantly between groups during the entire
24-week trial. For patients remaining in the study, ASI compos-
ite scores decreased signiﬁcantly, indicating a relevant reduction
in the severity of drug use (F(3/96) = 39.73; p = 0.000), alcohol use
(F(3/96) = 4.42; p = 0.006), employment (F(3/93) = 4.67; p = 0.004) and
psychiatric problems (F(3/96) = 6.31; p = 0.001), but without any dif-
ferences between groups. Three areas remained unchanged (legal,
family and medical problems). BDI (F(3/93) = 12.74; p = 0.000) and
SDS scores (F(3/90) = 33.45; p = 0.000) decreased signiﬁcantly over
time without any group differences.
3.6. Patients’ rating of CBT
There was no signiﬁcant difference in the number of attended
CBT sessions between the groups. Patients in the EG attended
on average 12.86 (SD = 5.7) sessions and those in the CG 11.68
(SD = 6.04) sessions (maximum 18 sessions).
Patients’ satisfaction with the CBT sessions after 12 and 24
weeks did not vary between groups. The question “Are you sat-
isﬁed with the therapy?” was  rated with a mean score of 4.78 after
12 weeks (EG = 4.81; CG = 4.75) and a mean score of 4.7 after 24
weeks (EG = 4.79; CG = 4.61), indicating a high satisfaction with CBT.score of 4.44 after 12 weeks (EG = 4.33; CG = 4.55) and 4.65 after 24
weeks (EG = 4.68; CG = 4.61), displaying a strong belief that therapy
helped.
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The general question “How do you feel now compared to study
tart” was asked after week 12 and after week 24. Of 41 patients, 38
92.7%) stated that they felt “better”, two (4.9%) stated “unchanged”,
nd one (2.4%) stated that he felt “worse” after 12 weeks. After
4 weeks, 35 patients (94.5%) felt “better” while one (2.7%) stated
e felt “unchanged” and one (2.7%) stated that he felt “a bit
orse”.
.7. Patients’ rating of CM
Patients in the EG liked the idea of winning prizes on a scale from
 to 5, with an average 4.67 (SD = 0.69). Nevertheless, they stated
hat the prizes were not “an additional incentive to become absti-
ent” (M = 3.39, SD = 0.85). Participants assigned to the EG earned
ean draws of 143.5 (SD = 137.7) out of the possible 435. Of these
raws, 69.2 (SD = 66.8) were non-winning, 60.6 (SD = 60.7) were
mall, 13.3 (SD = 14.7) were medium, and 0.4 (SD = 0.7) were jumbo
rizes. The average total cost of incentives for one patient was
76.34$ (SD = 630.72) for the 24-week period.
. Discussion
The present clinical trial makes an important contribution to
he literature, as it is to our knowledge the ﬁrst trial to examine
he effects of combined prizeCM plus individual CBT in cocaine-
ependent patients outside the USA. The objective of the present
tudy was to evaluate the acceptability and efﬁcacy of prizeCM
ombined with CBT compared to CBT alone in the European context.
e  expected the combination of prizeCM plus CBT to be more efﬁ-
acious than CBT alone. Our ﬁndings showed a slight advantage of
he combination group over CBT alone in the early treatment phase,
s indicated by signiﬁcantly higher proportions of cocaine-negative
rinalyses at certain time points. This result supports previous
ndings from the USA in cocaine-abusing or cocaine-dependent
atients (Kirby et al., 1998; McKay et al., 2010; Rawson et al.,
006) and in cocaine-dependent methadone-maintained patients
Epstein et al., 2003; Rawson et al., 2002; Rowan-Szal et al., 2005).
alf of the patients in both groups achieved at least 3 weeks of con-
inuous cocaine abstinence and there was a trend in favor of the EG
n achieving 9 weeks of continuous cocaine abstinence. Overall, we
ound a small effect of adding prizeCM to enhance cocaine absti-
ence in the present trial. Nevertheless, the results indicate that
oth interventions may  provide beneﬁts by signiﬁcantly reducing
ocaine use over the 24-week treatment period and these effects
ere sustained at 6-month follow-up. In contrast to USA trials, the
ombined intervention and CBT proved thus to be effective during
ctive treatment and at 6-month follow-up. The EG exhibited a pro-
ortion of 55.2% and the CG 41.9% cocaine-negative urinalyses at
he end of treatment (week 24), which is higher than those found
y Epstein et al. (2003).
In support of the ﬁndings of Carroll et al. (1994) and Hollon
2003) CBT alone also showed beneﬁcial and persistent effects
hroughout the 24 weeks of treatment and at 6-month follow-up.
What might account for these ﬁndings? One possibility is that
he comparison of prizeCM plus CBT to CBT only may  have con-
ributed to the non-signiﬁcant ﬁndings. Petry et al. (2005, 2012),
ho found signiﬁcant results with prizeCM in cocaine-dependent
utpatients conducted their trials in community-based clinics and
ompared CM to treatment as usual, and not to CBT. A prizeCM only
ondition might have been helpful in order to draw conclusions
egarding independent effects of the prizeCM component. How-
ver, for ethical reasons a prizeCM only condition was not feasible.
nother explanation could be that the value of our prizes may  have
een too low to produce a rewarding effect in our participants and
reater incentives might have provided more favorable outcomes.Dependence 145 (2014) 94–100 99
Finally, the sample size was  too small as indicated by the power
analysis.
The overall retention rate of 63.3% at week 24 in the present
trial was  high. Previous studies over 12 weeks (Epstein et al.,
2003; Rawson et al., 2006) found comparable retention rates. In
accordance with the ﬁndings of Epstein et al. (2003) (CBT = 79%;
combination = 69%), the two  groups in the present study did not
differ in retention, while Rawson et al. (2006) found a signiﬁcant
group difference (CBT = 40%; combination = 59%).
Furthermore, both interventions were effective in a clinical sam-
ple of patients with high rates of poly drug use and comorbid
psychiatric conditions, which supports previous ﬁndings (Magill
and Ray, 2009; Petry et al., 2013; Rash et al., 2008). One expla-
nation for this is that the effects of prizeCM and CBT in reducing
psychiatric symptoms are mediated by reductions in drug use.
Interestingly, trends in favoring prizeCM plus CBT were found
at 6-month follow-up. This ﬁnding suggests an additive effect of
the two  psychosocial approaches. Furthermore, prizeCM produced
a sustained effect beyond the cessation of incentives, which is in
support of the ﬁndings of McKay et al. (2010) and Epstein et al.
(2003).
Those patients who completed the trial showed highly signiﬁ-
cant reductions in SDS, BDI, and cocaine craving scores as well as
in 4 ASI composite scores (drug, alcohol, employment, psychiatric
problems), indicating clinical relevance of both treatment interven-
tions. Furthermore, participants in both intervention groups were
very satisﬁed and reported high acceptability of CBT and prizeCM.
Finally, those patients with higher frequency of cocaine use at base-
line had a higher risk of dropping out of the study. Therefore, we
suggest that these patients should have a detoxiﬁcation treatment
before beginning CBT or prizeCM plus CBT.
The generalizability of the present ﬁndings is limited by the sam-
ple size. The original targeted sample size could not be achieved,
due to difﬁculties in recruiting participants. First, the recruiting
process was initially planned at two sites, but data from one cen-
ter was  not included due to poor adherence to the study protocol
and incomplete data. Second, the recruitment had to be stopped
after 3 years due to running out of funds. One possible reason for
the difﬁculties in recruitment is, that the health care system in
Switzerland makes medical and drug services accessible for every-
one and social security in Switzerland is guaranteed in contrast to
the USA. Another explanation is that only cocaine-dependent not
cocaine abusing patients were eligible for the present study and
that many eligible patients did not want to attend the outpatient
clinic twice weekly. Patients’ ratings of helpfulness of the inter-
ventions were high in both treatment conditions. In conclusion,
our results indicate that combined prizeCM plus CBT or CBT alone
should be implemented in clinical practice in the European context
as evidence-based psychosocial interventions.
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